Share prices of genetic testing company Veracyte (NASDAQ: VCYT) plummeted 42% in 2022. It's no secret that growth stocks struggled mightily in 2022 amid high inflation and surging interest rates. Veracyte's top line is still quickly growing In the practice of medicine, making accurate diagnoses is of the utmost importance.